Menu
No results found.
📢 Scheduled Break in Updates
Please note that there will be no updates this week as I am taking a well-deserved holiday. Normal updates will resume on Saturday, 30th August. Thank you for your understanding.
Weekly Share Price & Valuation Overview
ApicHope Pharmaceutical Group Co., Ltd.
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical drugs. Its pediatric medicines include fuganlin and yiqi jianpi oral liquid, carboxymestrine oral solution, and xiaoer kechuanling oral liquid products; and clindamycin hydrochloride palmitate dispersible tablet, acetylguitaricin dry suspension, qinxiangqingjie oral liquid, levocetirizine hydrochloride drop, epstein hydrochloride granule, clindamycin hydrochloride palmitate granule, clindamycin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drop, montelukast sodium granule, acyclovir for injection, and oseltamivir phosphate capsule products. The company's chronic disease drugs comprise hepatocyte growth stimulating hormone and pentoxifylline for injections, kangshen granules, uqingshu granules, shenbai lotion products, compound monoammonium glycyrrhizinate S and lansoprazole for injections, houttuynia sodium tablets, omeprazole sodium and bromhexine hydrochloride for injections, huixinkang tablets, amlodipine benzenesulfonate dispersible tablets, yanhunin and sodium ferulate for injections, cyclic adenosine phosphate and ambroxol hydrochloride for injections, valsartan amlodipine tablets, and nifedipine controlled release tablets, as well as tricorutin, aceglutamide, vinpocetine, and doxofylline for injections. In addition, it offers compound xiangrui water, yinhuang oral liquid, and xiongdan chuanbei oral liquid products; venlafaxine hydrochloride sustained-release capsules; and levofloxacin hydrochloride, sodium ozagrel, brain protein hydrolysate, and ganciclovir for injections. The company was formerly known as ApicHope Pharmaceutical Co., Ltd and changed its name to ApicHope Pharmaceutical Group Co., Ltd. in December 2024. ApicHope Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Guangzhou, China.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 32.29B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 33.63B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 1.20B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 632.19M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY -240.07M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 2.67
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -1.29
- Shares Outstanding
- 451.69M
- Float Shares
- 159.93M
- Implied Shares Outstanding
- 451.69M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.22%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-19.93%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
52.49%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-48.49%
- ROA Return on assets: net income ÷ total assets.
-
-5.34%
- ROE Return on equity: net income ÷ shareholder equity.
-
-26.00%
- Revenue Growth Year-over-year revenue growth.
-
-39.50%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-43.70%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-43.70%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.71
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.26
- Total Cash Cash and equivalents.
- CNY 817.08M
- Total Debt Short + long-term interest-bearing debt.
- CNY 2.51B
- Net Debt Total debt − cash (negative = net cash).
- CNY 1.69B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -10.44
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY -566.30M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY -604.17M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-47.02%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-50.17%
- Cash Conversion (OpCF/EBITDA)
- 2.36
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.